Fig. 2

PLAU contributes to NSCLC growth, survival, and chemoresistance. (A) Western blot analysis of PLAU protein levels in A549 and H1299 cells transfected with indicated plasmids. (B) Assessment of the proliferation of NSCLC cells transfected with indicated plasmids by direct counting. ^*P < 0.05. (C) NSCLC cell proliferation as measured by EdU assay. Left, representative images of EdU (red) and Hoechst 33,342 (blue) staining of the cells; scale bar = 50 μm. Right, quantification of EdU-positive cells. ^*P < 0.05. (D) Colony formation assay. Left, representative wells showing colonies formed. Right, quantification of colony numbers. ^*P < 0.05. (E, F) Apoptosis analysis by annexin-V and propidium iodide staining. NSCLC cells transfected with indicated plasmids were cultured in the presence or absence of serum for 48 h before apoptosis assay. ^*P < 0.05. (G) NSCLC cells transfeced with indicated plasmids were treated with different concentrations of cisplatin for 72 h before viability assessment by the MTT method. (H, I) Tumorigenic studies. (H) Pictures of 4 representative tumors grown from A549 cells transfected with indicated plasmids. (I) Tumor volumes were calculated at indicated time points. ^*P < 0.05